AccuTOX-001 / Defence Therap - LARVOL DELTA

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER (Yahoo Finance) - “Defence Therapeutics…announce that it will be conducting a series of final studies to complete all requirement needed to initiate a Phase I trial for one of its leading AccuTOX candidate against breast cancer…‘We are actively pursuing our AccuTOX program to initiate a Phase I trial against breast cancer in Q1-Q2 of 2022’…'The secondary objectives would be to compare the potency of AccuTOX-001 as stand-alone or combination therapy with currently used immune-checkpoint inhibitors’…Once completed, this data along with the GLP study scheduled in Q4 of 2021 will be compiled and presented to the FDA to have clearance for a Phase I trial against breast cancer.”

New P1 trial • P1 data • Breast Cancer • Oncology